Bristol Myers Short Ratio vs. Z Score

BMY Stock  USD 53.25  0.70  1.33%   
Based on Bristol Myers' profitability indicators, Bristol Myers Squibb is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in April. Profitability indicators assess Bristol Myers' ability to earn profits and add value for shareholders. At this time, Bristol Myers' Price To Sales Ratio is fairly stable compared to the past year. Days Of Sales Outstanding is likely to rise to 129.98 in 2024, whereas Operating Cash Flow Sales Ratio is likely to drop 0.17 in 2024. At this time, Bristol Myers' Operating Income is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1.5 B in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (1.6 B) in 2024.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.7624
Sufficiently Up
Slightly volatile
Operating Profit Margin0.250.3831
Way Down
Pretty Stable
For Bristol Myers profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bristol Myers to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bristol Myers Squibb utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bristol Myers's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bristol Myers Squibb over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bristol-Myers Squibb Z Score vs. Short Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth.
Bristol Myers Squibb is rated fourth in short ratio category among related companies. It is rated fifth in z score category among related companies totaling about  1.45  of Z Score per Short Ratio. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.

Bristol Z Score vs. Short Ratio

Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Bristol Myers

Short Ratio

 = 

Short Interest

Average Trading Volume

 = 
2.24 X
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Bristol Myers

Z Score

 = 

Sum Of

5 Factors

 = 
3.24
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Bristol Z Score Comparison

Bristol Myers is currently under evaluation in z score category among related companies.

Bristol Myers Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bristol Myers, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bristol Myers will eventually generate negative long term returns. The profitability progress is the general direction of Bristol Myers' change in net profit over the period of time. It can combine multiple indicators of Bristol Myers, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2024
Accumulated Other Comprehensive Income-1.5 B-1.6 B
Operating Income17.2 B18.1 B
Income Before Tax8.4 B4.2 B
Total Other Income Expense Net1.4 B1.5 B
Net IncomeB8.4 B
Income Tax Expense400 M380 M
Net Income Applicable To Common Shares5.7 BB
Net Income From Continuing Ops8.3 B8.7 B
Non Operating Income Net Other-662.4 M-629.3 M
Net Interest Income-1.1 B-1.2 B
Interest Income2.1 B2.2 B
Change To Netincome-970.2 M-921.7 M
Net Income Per E B T 0.95  0.64 

Bristol Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bristol Myers. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bristol Myers position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bristol Myers' important profitability drivers and their relationship over time.

Use Bristol Myers in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Bristol Myers Pair Trading

Bristol Myers Squibb Pair Trading Analysis

The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bristol Myers position

In addition to having Bristol Myers in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Power Assets Thematic Idea Now

Power Assets
Power Assets Theme
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out Trending Equities.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
To fully project Bristol Myers' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bristol-Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bristol Myers' income statement, its balance sheet, and the statement of cash flows.
Potential Bristol Myers investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bristol Myers investors may work on each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.